JP2022513055A - 形質転換されたt細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法 - Google Patents
形質転換されたt細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法 Download PDFInfo
- Publication number
- JP2022513055A JP2022513055A JP2021526674A JP2021526674A JP2022513055A JP 2022513055 A JP2022513055 A JP 2022513055A JP 2021526674 A JP2021526674 A JP 2021526674A JP 2021526674 A JP2021526674 A JP 2021526674A JP 2022513055 A JP2022513055 A JP 2022513055A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- gene
- cell
- natural killer
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 157
- 210000004700 fetal blood Anatomy 0.000 title claims abstract description 71
- 238000000034 method Methods 0.000 title claims abstract description 64
- 238000012258 culturing Methods 0.000 title claims abstract description 63
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 62
- 210000004027 cell Anatomy 0.000 claims abstract description 336
- 108090000623 proteins and genes Proteins 0.000 claims description 120
- 210000005087 mononuclear cell Anatomy 0.000 claims description 59
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 58
- 108010002350 Interleukin-2 Proteins 0.000 claims description 26
- 102000000588 Interleukin-2 Human genes 0.000 claims description 26
- 108010042215 OX40 Ligand Proteins 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 12
- 241000713666 Lentivirus Species 0.000 claims description 11
- 108010074108 interleukin-21 Proteins 0.000 claims description 9
- 102000003812 Interleukin-15 Human genes 0.000 claims description 7
- 108090000172 Interleukin-15 Proteins 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 7
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 102000013462 Interleukin-12 Human genes 0.000 claims description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims description 3
- 102000003810 Interleukin-18 Human genes 0.000 claims description 2
- 108090000171 Interleukin-18 Proteins 0.000 claims description 2
- 229940127174 UCHT1 Drugs 0.000 claims description 2
- 230000022534 cell killing Effects 0.000 abstract description 13
- 239000003814 drug Substances 0.000 abstract description 9
- 229940124597 therapeutic agent Drugs 0.000 abstract description 8
- 230000002062 proliferating effect Effects 0.000 abstract description 7
- 238000012136 culture method Methods 0.000 abstract description 5
- 238000010586 diagram Methods 0.000 abstract 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 56
- 239000002609 medium Substances 0.000 description 39
- 230000014509 gene expression Effects 0.000 description 33
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 29
- 230000035755 proliferation Effects 0.000 description 24
- 102100026890 Tumor necrosis factor ligand superfamily member 4 Human genes 0.000 description 22
- 210000002381 plasma Anatomy 0.000 description 22
- 206010028980 Neoplasm Diseases 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 18
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 17
- 230000004083 survival effect Effects 0.000 description 16
- 239000003550 marker Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000012980 RPMI-1640 medium Substances 0.000 description 13
- 230000009261 transgenic effect Effects 0.000 description 12
- 108700019146 Transgenes Proteins 0.000 description 11
- 238000003501 co-culture Methods 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 102000029791 ADAM Human genes 0.000 description 8
- 108091022885 ADAM Proteins 0.000 description 8
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 8
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 description 7
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 7
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 description 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 6
- 102100038077 CD226 antigen Human genes 0.000 description 6
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 6
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 6
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 6
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 6
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 description 6
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 4
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 4
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000005251 gamma ray Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000012146 running buffer Substances 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 108700025316 aldesleukin Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- -1 mbIL-21 Proteins 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 229940087463 proleukin Drugs 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 210000001991 scapula Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 210000000779 thoracic wall Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 102000043279 ADAM17 Human genes 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PNVJTZOFSHSLTO-UHFFFAOYSA-N Fenthion Chemical compound COP(=S)(OC)OC1=CC=C(SC)C(C)=C1 PNVJTZOFSHSLTO-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 102100030703 Interleukin-22 Human genes 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010077854 Natural Killer Cell Receptors Proteins 0.000 description 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000021601 lentivirus infection Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1164—NK cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
- C12N2506/025—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells from extra-embryonic cells, e.g. trophoblast, placenta
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
mental Hematology 36(1):61-68,2008)。
細胞生存率(%)=(生存細胞数/総細胞数)×100
また、臍帯血単核細胞から分離されたCD3(-)細胞を、遺伝子が導入されたフィーダー細胞と21日間共培養した後、代表的なナチュラルキラー細胞の受容体(receptor)の発現を分析した。
% of killing=(Sampleウェル平均蛍光値-Sponウェル平均蛍光値)/{(Maxウェル平均蛍光値+A)-Sponウェル平均蛍光値}×100
Claims (26)
- 形質転換されたCD4+T細胞と種細胞を共培養することを含むナチュラルキラー細胞の培養方法。
- 前記形質転換されたCD4+T細胞は、4-1BBL遺伝子、mbIL-21遺伝子、OX40L遺伝子及びmTNF-α遺伝子からなる群から選ばれる少なくとも一つの遺伝子が発現するものである、請求項1に記載の方法。
- 前記4-1BBL遺伝子は、配列番号1で表示されるアミノ酸配列をコードする塩基配列である、請求項2に記載の方法。
- 前記配列番号1で表示されるアミノ酸配列をコードする塩基配列は、配列番号2で表示される塩基配列である、請求項3に記載の方法。
- 前記mbIL-21遺伝子は、配列番号3で表示されるアミノ酸配列をコードする塩基配列である、請求項2に記載の方法。
- 前記配列番号3で表示されるアミノ酸配列をコードする塩基配列は、配列番号4で表示される塩基配列である、請求項5に記載の方法。
- 前記OX40L遺伝子は、配列番号5で表示されるアミノ酸配列をコードする塩基配列である、請求項2に記載の方法。
- 前記配列番号5で表示されるアミノ酸配列をコードする塩基配列は、配列番号6で表示される塩基配列である、請求項7に記載の方法。
- 前記mTNF-α遺伝子は、配列番号8で表示されるアミノ酸配列をコードする塩基配列である、請求項2に記載の方法。
- 前記配列番号8で表示されるアミノ酸配列をコードする塩基配列は、配列番号9で表示される塩基配列である、請求項9に記載の方法。
- 前記遺伝子は、組換えレンチウイルスを介して導入されたものである、請求項2に記載の方法。
- 前記CD4+T細胞は、4-1BBL遺伝子又はmbIL-21遺伝子が発現するものである、請求項1に記載の方法。
- 前記CD4+T細胞は、4-1BBL遺伝子及びmbIL-21遺伝子が発現するものである、請求項1に記載の方法。
- 前記CD4+T細胞は、4-1BBL遺伝子、mbIL-21遺伝子及びmTNF-α遺伝子が発現するものである、請求項1に記載の方法。
- 前記CD4+T細胞は、4-1BBL遺伝子、mbIL-21遺伝子、OX40L遺伝子及びmTNF-α遺伝子が発現するものである、請求項1に記載の方法。
- 前記CD4+T細胞は、Hut78、H9、Jurkat、Loucy、Molt-3、Molt-13、Peer、RPMI8402及びTALL-01細胞からなる群から選ばれるいずれか一つである、請求項1に記載の方法。
- 前記種細胞は、臍帯血(cord blood)由来の単核細胞である、請求項1に記載の方法。
- 前記種細胞は、CD3(+)細胞が除去された細胞である、請求項1に記載の方法。
- 前記形質転換されたCD4+T細胞と前記種細胞の比率を0.1:1~50:1に混合して培養する、請求項1に記載の方法。
- 前記種細胞は、フィーダー細胞と1回混合して5日~60日間培養するか、或いはフィーダー細胞と2回以上混合して60日以上培養する、請求項1に記載の方法。
- 抗CD3抗体及びインターロイキンタンパク質が含まれている培地で培養する、請求項1に記載の方法。
- 前記抗CD3抗体は、OKT3、UCHT1及びHIT3aからなる群から選ばれるいずれか一つを含む、請求項21に記載の方法。
- 前記インターロイキンタンパク質は、IL-2、IL-12、IL-15、IL-18及びIL-21からなる群から選ばれるいずれか一つを含む、請求項21に記載の方法。
- 請求項1のナチュラルキラー細胞の培養方法によって製造されたナチュラルキラー細胞。
- 形質転換されたCD4+T細胞を有効成分として含むナチュラルキラー細胞の培養用組成物。
- 前記形質転換されたCD4+T細胞は、4-1BBL遺伝子、mbIL-21遺伝子、OX40L遺伝子及びmTNF-α遺伝子からなる群から選ばれる少なくとも一つの遺伝子が発現するものである、請求項25に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0139722 | 2018-11-14 | ||
KR20180139722 | 2018-11-14 | ||
PCT/KR2019/015469 WO2020101361A1 (ko) | 2018-11-14 | 2019-11-13 | 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법 |
KR1020190145068A KR102338957B1 (ko) | 2018-11-14 | 2019-11-13 | 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법 |
KR10-2019-0145068 | 2019-11-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022513055A true JP2022513055A (ja) | 2022-02-07 |
JP7179986B2 JP7179986B2 (ja) | 2022-11-29 |
Family
ID=70914224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021526674A Active JP7179986B2 (ja) | 2018-11-14 | 2019-11-13 | 形質転換されたt細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20240084256A1 (ja) |
EP (1) | EP3892721A4 (ja) |
JP (1) | JP7179986B2 (ja) |
KR (1) | KR102338957B1 (ja) |
CN (1) | CN113383069A (ja) |
AU (1) | AU2019381526B2 (ja) |
CA (1) | CA3120085A1 (ja) |
IL (1) | IL283176A (ja) |
SG (1) | SG11202104662UA (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114214286A (zh) * | 2021-12-17 | 2022-03-22 | 上海纳米技术及应用国家工程研究中心有限公司 | 一种用于高效扩增nk细胞的k562-ox40l细胞系的制备方法 |
CN115028737A (zh) * | 2022-05-26 | 2022-09-09 | 青岛麦迪赛斯医疗技术有限公司 | 一种nk细胞培养用滋养细胞 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013006793A (ja) * | 2011-06-24 | 2013-01-10 | Tella Inc | Nk細胞を増幅するための組成物及び方法 |
JP2013027385A (ja) * | 2011-06-24 | 2013-02-07 | Kyushu Univ | Nk細胞の増幅方法 |
WO2014188680A1 (ja) * | 2013-05-22 | 2014-11-27 | 国立大学法人九州大学 | Nk細胞の調製方法 |
JP2017525370A (ja) * | 2014-08-21 | 2017-09-07 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍壊死因子スーパーファミリーおよびtnf様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびtnf様リガンドムテインを調製および使用する方法 |
JP2018520993A (ja) * | 2015-05-07 | 2018-08-02 | アジェナス インコーポレイテッド | 抗ox40抗体及びその使用方法 |
WO2018197859A1 (en) * | 2017-04-24 | 2018-11-01 | Imperial Innovations Limited | Cancer treatment |
JP7039623B2 (ja) * | 2017-05-26 | 2022-03-22 | グリーン・クロス・ラブ・セル・コーポレイション | 形質転換されたt細胞を用いてナチュラルキラー細胞を培養する方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3357338A1 (en) * | 2007-03-30 | 2018-08-08 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
CN102559600A (zh) * | 2011-12-29 | 2012-07-11 | 上海交通大学医学院 | 一种人工抗原递呈细胞及其在nk细胞扩增中的应用 |
US9938498B2 (en) * | 2012-05-07 | 2018-04-10 | Nkmax Co., Ltd. | Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells |
CN105602899B (zh) * | 2014-11-25 | 2019-03-08 | 天津天锐生物科技有限公司 | 一种白细胞介素21和4-1bbl诱导外周血单个核细胞中nk细胞增殖的方法 |
KR101697473B1 (ko) * | 2014-11-26 | 2017-01-18 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
CN108300697A (zh) * | 2017-01-13 | 2018-07-20 | 上海恒润达生生物科技有限公司 | 一种滋养细胞刺激nk细胞扩增的方法和用途 |
CN108300693A (zh) * | 2018-01-25 | 2018-07-20 | 河北省健海生物芯片技术有限责任公司 | 一种自然杀伤细胞体外扩增方法 |
-
2019
- 2019-11-13 US US17/293,835 patent/US20240084256A1/en active Pending
- 2019-11-13 EP EP19885404.4A patent/EP3892721A4/en active Pending
- 2019-11-13 AU AU2019381526A patent/AU2019381526B2/en active Active
- 2019-11-13 JP JP2021526674A patent/JP7179986B2/ja active Active
- 2019-11-13 CN CN201980075094.XA patent/CN113383069A/zh active Pending
- 2019-11-13 SG SG11202104662UA patent/SG11202104662UA/en unknown
- 2019-11-13 KR KR1020190145068A patent/KR102338957B1/ko active IP Right Grant
- 2019-11-13 CA CA3120085A patent/CA3120085A1/en active Pending
-
2021
- 2021-05-13 IL IL283176A patent/IL283176A/en unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013006793A (ja) * | 2011-06-24 | 2013-01-10 | Tella Inc | Nk細胞を増幅するための組成物及び方法 |
JP2013027385A (ja) * | 2011-06-24 | 2013-02-07 | Kyushu Univ | Nk細胞の増幅方法 |
WO2014188680A1 (ja) * | 2013-05-22 | 2014-11-27 | 国立大学法人九州大学 | Nk細胞の調製方法 |
JP2017525370A (ja) * | 2014-08-21 | 2017-09-07 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍壊死因子スーパーファミリーおよびtnf様リガンドムテインならびに腫瘍壊死因子スーパーファミリーおよびtnf様リガンドムテインを調製および使用する方法 |
JP2018520993A (ja) * | 2015-05-07 | 2018-08-02 | アジェナス インコーポレイテッド | 抗ox40抗体及びその使用方法 |
WO2018197859A1 (en) * | 2017-04-24 | 2018-11-01 | Imperial Innovations Limited | Cancer treatment |
JP7039623B2 (ja) * | 2017-05-26 | 2022-03-22 | グリーン・クロス・ラブ・セル・コーポレイション | 形質転換されたt細胞を用いてナチュラルキラー細胞を培養する方法 |
Non-Patent Citations (2)
Title |
---|
DATABASE GENBANK [ONLINE], ACCESSION NO.NM_021803.3, 17-JUN-2018 UPLOADED, ZHANG L, ET AL., DEFINIT, JPN6022016379, ISSN: 0004769264 * |
MIN BOKYUNG, "IDENTIFICATION OF NK CELL COSTIMULATORY RECEPTORS FOR LARGE-SCALE EXPANSION OF NK CEL, JPN6022016378, ISSN: 0004769263 * |
Also Published As
Publication number | Publication date |
---|---|
CN113383069A (zh) | 2021-09-10 |
AU2019381526B2 (en) | 2023-02-23 |
US20240084256A1 (en) | 2024-03-14 |
EP3892721A4 (en) | 2022-08-31 |
SG11202104662UA (en) | 2021-06-29 |
JP7179986B2 (ja) | 2022-11-29 |
AU2019381526A1 (en) | 2021-06-03 |
KR20200056333A (ko) | 2020-05-22 |
KR102338957B1 (ko) | 2021-12-14 |
CA3120085A1 (en) | 2020-05-22 |
EP3892721A1 (en) | 2021-10-13 |
IL283176A (en) | 2021-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7039623B2 (ja) | 形質転換されたt細胞を用いてナチュラルキラー細胞を培養する方法 | |
US11560548B2 (en) | Immune cells expressing membrane-bound interleukin 15 (mbIL15) and uses thereof | |
US11690872B2 (en) | Methods for expanding and activating γδ T cells for the treatment of cancer and related malignancies | |
JP5156382B2 (ja) | T細胞集団の製造方法 | |
JP6971986B2 (ja) | 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞 | |
JP7450892B2 (ja) | Nk細胞のための人工hla陽性フィーダー細胞株及びその使用 | |
JP2018501779A (ja) | T細胞を利用したナチュラルキラー細胞の培養方法 | |
US20220064599A1 (en) | Car nk cells | |
JP7179986B2 (ja) | 形質転換されたt細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法 | |
WO2019177151A1 (ja) | 遺伝子改変細胞及びその作製方法 | |
CN114835820B (zh) | 用于基因改造的多能干细胞及、自然杀伤细胞的嵌合型Fc受体 | |
AU2018372206B2 (en) | Methods for activating, modifying and expanding gamma delta T cells for the treatment of cancer and related malignancies | |
JP2010099022A (ja) | リンパ球の製造方法 | |
JP2010094123A (ja) | リンパ球の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210514 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220805 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20221101 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20221116 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7179986 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |